In a report released today, Matthew Gillmor from Robert W. Baird maintained a Buy rating on Allscripts (NASDAQ: MDRX), with a price target of $14. The company’s shares opened today at $10.25, close to its 52-week low of $9.65.
According to TipRanks.com, Gillmor is a 5-star analyst with an average return of 17.6% and a 62.5% success rate. Gillmor covers the Services sector, focusing on stocks such as Addus Homecare Corp, Acadia Healthcare, and Hms Holdings Corp.
Allscripts has an analyst consensus of Moderate Buy, with a price target consensus of $14.43, representing a 40.8% upside. In a report released today, Maxim Group also maintained a Buy rating on the stock with a $18 price target.
.
See today’s analyst top recommended stocks >>
Based on Allscripts’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $64.82 million. In comparison, last year the company had a GAAP net loss of $28.59 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allscripts Healthcare Solutions, Inc. engages in the provision of clinical, financial, connectivity, information solutions, and related professional services. It operates through the following segments: Clinical and Financial Solutions; Population Health; and Netsmart.
